Navigation Links
Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
Date:1/8/2010

ss. He also was managing director of SmithKline's pharmaceutical operations in the Philippines. He also held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America.

Mr. Roche serves as a member of the board of directors for Intercept Pharmaceuticals.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL® (armodafinil) Tablets [C-IV], TREANDA® (bendamustine hydrochloride) for Injection, AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, GABITRIL® (tiagabine hydrochloride), PROVIGIL® (modafinil) Tablets [C-IV] and ACTIQ® (oral transmucosal fentanyl citra
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
2. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
3. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
4. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
5. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
10. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
11. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Mass. , July 27, 2015 ... of Merck KGaA of Darmstadt, ... with celares GmbH to provide pegylation services to ... service offering enabled by the collaboration includes feasibility ... milligram to gram quantities required for pilot and ...
(Date:7/27/2015)... , July 27, 2015  Endo International plc (NASDAQ: ... 2015 financial results before the open of the U.S. financial ... management team will host a conference call and webcast at ... number to access the call is U.S./ Canada ... is 93183256. Please dial in 10 minutes prior to the ...
(Date:7/27/2015)... PITTSBURGH , July 27, 2015  Mylan N.V. ... regarding Teva,s (NYSE and TASE: TEVA) announcement of its ... and its withdrawal of its unsolicited expression of interest ... Robert J. Coury stated: "We congratulate Teva on ... their continued, and potentially enhanced, commitment to the generics ...
Breaking Medicine Technology:EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 2EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH 3Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 2Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 3Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 4Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 5Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 6Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 7Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 8Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit 9
... Safety Profile of the Intramuscular Formulation,of Peramivir ... BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ --,BioCryst ... I,clinical studies of an intramuscular (i.m.) formulation ... of Influenza Conference in,Toronto, Ontario, Canada. This ...
... 70 abstracts highlight VELCADE efficacy in broad range,of ... Mass., June 19, 2007 /PRNewswire-FirstCall/ --,Millennium Pharmaceuticals, Inc. ... therapy with unsurpassed single-agent,efficacy for patients with previously ... upcoming International Myeloma,Workshop (IMW) in Kos, Greece, June ...
Cached Medicine Technology:BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 2BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 3BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 4BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 5BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
(Date:7/27/2015)... ... July 28, 2015 , ... Dr. Robert G. Schwartz ... practice has teamed up with Realief Neuropathy Centers in order to offer his patients ... the signs and symptoms of peripheral neuropathy. , Peripheral neuropathy is a disease caused ...
(Date:7/27/2015)... ... July 27, 2015 , ... Specific cardiovascular risk factors, ... brain volumes that may be early indicators of Alzheimer’s disease and dementia, according ... that vascular risk factors damage the brain and can result in cognitive impairment,” ...
(Date:7/27/2015)... Madre, CA (PRWEB) , ... July 27, 2015 ... ... of healthcare today, especially in wound center management. Earlier this year Wound ... wound care education and training for WCA wound centers. Customized learning paths ...
(Date:7/27/2015)... Los Angeles, CA (PRWEB) , ... July 27, 2015 , ... ... See the Derm for 7 Common Skin Issues,” describes common skin issues such as ... the technology available for cosmetic dermatologists to treat them. The treatment options listed include ...
(Date:7/27/2015)... ... July 27, 2015 , ... Send ... and mobile collaboration, announced today the latest software release for ... and other feature enhancements. , This software release gives the widely used online ...
Breaking Medicine News(10 mins):Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2
... a key molecule that controls the growth, spread and survival ... toward new and better treatment options for pancreatic cancer . ... Beta molecule plays in pancreatic cancer and that they have ... and survival through its effect on NF Kappa B -- ...
... the drug alendronate (Fosamax) can reduce the risk of vertebral ... not osteoporosis. 3,737 postmenopausal women between ages 55 and 80 ... -2.5 were evaluated . About half the women randomly received ... thereafter while the other half took a placebo. ,The ...
... its growth factors aren’t just produced in the pancreas, but ... areas of the brain//, the result can be brain cell ... people with Alzheimer’s. ,The research was conducted in rats, ... IGF I and IGF II were produced in the nerve ...
... well known that HIV patients are at an increased risk ... study shows // aggressive antiretroviral therapy may help lower that ... antiretroviral therapy was associated with a lower incidence of Kaposi ... on more than 7,300 patients infected with HIV and the ...
... Intravenous administration of the drug tezosentan did not improve worsening ... failure // despite high hopes. The above fact was found ... to date. The study was conducted to evaluate if something ... order to speed up hospital discharge and prevent them from ...
... that how much we drink may be decided by a ... gene called DRD2 Taq1A(C32806T) polymorphism and social alcohol drinking may ... stronger gene of this type will tend to drink alcohol ... The gene is responsible for enhancing the pleasure that is ...
Cached Medicine News:
... camera system for high resolution photomicrography. The ... of the highest color fidelity, resolution and ... expect perfect images due to many unique ... innovative readout modes. The Leica DFC480 is ...
This compact photomicrographic system assures simple operation to achieve the exposure accuracy required for sophisticated photomicrography in most research and clinical environments....
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Stat Stain is ideal for stat, routine ... blood smears (10-15 seconds) and bone marrow ... finely dispersed stain particles which yield excellent ... many of the steps involved in the ...
Medicine Products: